On February 24, 2022, Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, announced the completion of a $110 million financing. The round is led by Cowen Healthcare Investments, with participation from new investors Neuberger Berman, Hitachi Ventures, Laurion Capital, and Monashee Investment Management. Existing investors Northpond Ventures, aMoon, Khosla Ventures, Optum Ventures, Echo Health Ventures, and Alumni Ventures also are participating. Scipher has raised $227 million total to date. Wilson Sonsini Goodrich & Rosati advised Scipher Medicine on patent matters related to the transaction.

Scipher is bringing precision medicine to patients with autoimmune diseases by commercializing blood tests that reveal a person’s unique molecular disease signature and matching it to the most effective existing therapy, ensuring providers and payers can select optimal therapy from day one. Molecular and clinical data generated from tested patients further fuel the development of targeted, more effective therapeutics through pharma collaborations.

The Wilson Sonsini team that advised Scipher Medicine on patent matters related to the transaction included Uale Taotafa, Shane Crippen, and Ali Alemozafar.

For more information, please see Scipher Medicine's press release.